Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the combination of bleximenib with venetoclax VEN and azacitidine AZA compared to placebo with VEN and AZA alone for treating adults newly diagnosed with Acute Myeloid Leukemia AML who have specific gene mutations in NPM1 or KMT2A. This phase 3 randomized, double-blind study is designed for participants ineligible for intensive chemotherapy, aiming to understand how these treatments work in this population. Participants will receive treatment in 28-day cycles until disease progression or unacceptable side effects occur. One group will take oral bleximenib alongside oral venetoclax and intravenous or subcutaneous azacitidine, while the other group receives a placebo plus venetoclax and azacitidine. Treatment continues with regular cycles, and the study monitors effects over time. Throughout the study, participants will be assessed for response, including complete remission rates and overall survival, for up to more than four years. Researchers will also track event-free survival, duration and timing of remission, transfusion independence, adverse events, and blood levels of bleximenib. Safety and laboratory tests will be conducted regularly to monitor participant health and treatment effects.
Actively Recruiting
Researchers are studying the effects of elritercept TAK-226, KER-050 in treating anemia in adults with very low, low, or intermediate-risk myelodysplastic syndromes MDS who require regular blood transfusions. This Phase 3, randomized, double-blind, placebo-controlled trial aims to find out how well elritercept reduces the need for red blood cell RBC transfusions, especially over longer periods or in adults with high transfusion needs. The study also monitors the safety and tolerability of elritercept. Participants who qualify will be randomly assigned in a 21 ratio to receive either elritercept or a matching placebo by subcutaneous injection every 4 weeks. The study includes a Primary Phase lasting 24 weeks, followed by a Secondary Phase of an additional 24 weeks, during which the same blinded treatment continues. Study visits are scheduled every 2 weeks for the first 6 cycles and every 4 weeks thereafter. An Extension Phase allows eligible participants to continue treatment until they choose to stop or the study is unblinded. Throughout the study, participants will undergo regular assessments including MDS disease evaluations every 24 weeks, laboratory tests, vital sign monitoring, and safety follow-up visits every 4 weeks for 8 weeks after the last dose. Long-term follow-up will continue quarterly for up to 5 years to monitor ongoing health status. The main outcome measured is the percentage of participants achieving transfusion independence for at least 8 weeks during the first 24 weeks of treatment.
Actively Recruiting
Researchers are evaluating axatilimab combined with corticosteroids compared to placebo plus corticosteroids as the initial treatment for moderate or severe chronic graft-versus-host disease cGVHD. The purpose is to compare the effectiveness of axatilimab in improving event-free survival and other clinical outcomes in patients who have developed cGVHD after allogeneic hematopoietic cell transplantation. This is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Incyte Corporation. Participants will receive either axatilimab or placebo via intravenous infusion along with corticosteroids given orally or intravenously at protocol-defined doses. The study involves two experimental arms one with axatilimab plus corticosteroids and another with placebo plus corticosteroids. Treatment will be administered according to the study protocol, and participants will be monitored for up to three years to assess efficacy and safety outcomes. During the study, participants will undergo regular assessments including monitoring event-free survival, objective response, overall response, survival rates, and corticosteroid dose reductions. Laboratory tests will measure changes in monocyte counts and bone markers. Safety will be closely tracked through adverse event reporting. The total participation duration can be up to approximately five years, including the treatment period and long-term follow-up for outcomes and safety monitoring.
Actively Recruiting
This research aims to evaluate the long-term safety of luspatercept in participants who have previously taken part in other luspatercept clinical trials for conditions such as Myelodysplastic Syndromes MDS, Beta-thalassemia, and Myeloproliferative Neoplasm-associated Myelofibrosis. It is a Phase 3b, open-label, single-arm rollover study designed to continue monitoring participants who tolerated previous luspatercept treatment and may benefit from ongoing therapy, as well as those in post-treatment follow-up phases. Participants transitioning from prior luspatercept studies will enter a Transition Phase defined by an enrollment visit. Those continuing treatment will receive luspatercept injections subcutaneously at the same dose and schedule as their parent trial, administered by study staff at clinical sites. The study includes a Treatment Phase for ongoing luspatercept administration and a Follow-up Phase comprising a 42-day safety follow-up after the last dose and a long-term post-treatment follow-up phase lasting at least 5 years to monitor overall survival and progression to malignancies. Throughout the study, participants will be regularly assessed for adverse events, progression to high-risk MDS or AML, and development of other malignancies or treatment-related masses. Safety parameters are evaluated during the 42-day follow-up, while long-term survival and disease progression are monitored every six months for at least five years. The study will conclude when all participants have completed five years of combined treatment and follow-up.
Actively Recruiting
Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.
Actively Recruiting
Researchers are studying acute myeloid leukemia AML, a fast-growing cancer mainly affecting bone marrow cells, especially in older adults. This study focuses on how the inflammasome, a part of the immune system that controls inflammation, affects AML development and the response to chemotherapy. Understanding this connection may help explain why some patients respond differently to treatment and could guide the creation of personalized therapies. Patients with newly diagnosed AML will have biological samples, including peripheral blood and bone marrow, collected and analyzed before and after their first-line chemotherapy. The study includes both prospective and retrospective parts, with patients undergoing standard treatments following clinical guidelines. Common chemotherapy regimens include intensive protocols like 37 with daunorubicin and cytarabine, sometimes combined with other drugs, and non-intensive treatments such as azacitidine with venetoclax. During the study, participants will follow their usual diagnostic and treatment plans while additional blood and bone marrow samples are collected for research purposes. Researchers will perform tests like inflammasome activity assays, gene expression analysis, and immunophenotyping to evaluate treatment response and disease progression. The main outcome is to measure inflammasome activity at diagnosis, in case of treatment failure, and six months after starting chemotherapy. The observation period lasts up to six months, with data collected to monitor disease status and treatment effects.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Myelodysplastic syndromes MDS primarily affect older adults and involve problems with blood cell production, leading to anemia, low white blood cells, and low platelets. These conditions often cause patients to depend on red blood cell transfusions and carry risks like infection and bleeding. This research evaluates luspatercept, a protein designed to help mature red blood cells, in adults with MDS who have a specific chromosome deletion del5q and who are resistant or intolerant to prior treatments like lenalidomide. The study focuses on patients with low to intermediate risk MDS and aims to assess whether luspatercept can reduce the need for transfusions. Participants will receive luspatercept injections under the skin every three weeks, starting at a dose of 1.0 mgkg, with possible increases up to 1.75 mgkg. The study has a screening period, followed by a two-year treatment phase where patients receive the drug and are closely monitored. After treatment, there is a three-year follow-up to observe longer-term effects. Researchers will track responses such as transfusion independence, hemoglobin levels, quality of life, and safety during and after treatment. Throughout the study, participants will have regular visits for assessments including blood tests, quality of life questionnaires, and monitoring for side effects. The main outcome is whether patients achieve at least eight weeks without needing red blood cell transfusions within the first 24 weeks. Additional measures include long-term transfusion independence, duration of response, reduction in transfusions, changes in iron levels, and overall safety over five years. The total participation lasts up to five years, ensuring comprehensive evaluation of luspatercepts effects.
Actively Recruiting
This research aims to evaluate the effects of a home-based exercise program on people with chronic kidney disease CKD at stages III or IV who also have peripheral artery disease PAD at stages I to III. These conditions together increase cardiovascular risk and complications like mortality and limb amputations. The study focuses on improving physical function and quality of life by comparing exercise therapy to usual care in a randomized controlled trial involving 100 patients aged 18 to 80 years without contraindications to exercise. Participants will be randomly assigned to one of two groups. The exercise group will follow a 6-month home walking program involving two daily 10-minute interval walking sessions at an increasing speed controlled by a digital metronome. Training intensity is light to moderate, with two hospital visits at 1 and 3 months to adjust the exercise plan and encourage adherence via a digital app. The control group will receive standard care including optimal medical treatment and nutritional advice. Patients in both groups will be assessed at the start, at 6 months when the exercise ends, and at 12 months for follow-up. Researchers will measure walking ability using the 6-minute walking test as the primary outcome, along with limb blood flow, strength, body composition, bone density, quality of life, kidney function, hospitalizations, and mortality. Assessments are done by blinded evaluators to track the effects of the intervention over time.
Actively Recruiting
Researchers are conducting an ongoing international observational program called the Fabry Registry to track routine clinical outcomes in patients diagnosed with Fabry disease. This registry includes all patients regardless of their treatment status and aims to improve understanding of the diseases variability, progression, and natural history, including in female patients. It also supports development of monitoring recommendations, characterization of the Fabry population, and evaluation of the long-term safety and effectiveness of Fabrazyme4. The study features a Fabry Pregnancy Sub-registry, which observes pregnancy outcomes in women enrolled in the main registry. This sub-registry collects data on medical and obstetric history, pregnancy, birth outcomes, and infant growth up to 36 months postpartum. Neither the main registry nor the pregnancy sub-registry involve experimental interventions, and patients receive standard care as determined by their treating physicians. Participants undergo clinical assessments and receive their usual care during the registry. Data collected includes safety and effectiveness of treatments like Fabrazyme4 over long periods, as well as pregnancy complications and infant growth measurements. The study is designed to last until 2034, with ongoing monitoring and data collection to support patient care and research without altering treatment plans.
1-10 of 20
1